Exagen (NASDAQ:XGN) CEO John Aballi Sells 15,698 Shares

Exagen Inc. (NASDAQ:XGN) CEO John Aballi sold 15,698 shares of the firm’s stock in a transaction that occurred on Tuesday, March 3rd. The stock was sold at an average price of $3.62, for a total transaction of $56,826.76. Following the completion of the transaction, the chief executive officer directly owned 687,299 shares in the company, valued at approximately $2,488,022.38. The trade was a 2.23% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

John Aballi also recently made the following trade(s):

• On Tuesday, February 24th, John Aballi sold 11,430 shares of Exagen stock. The shares were sold at an average price of $3.61, for a total transaction of $41,262.30.

Exagen Stock Performance

Shares of Exagen stock traded up $0.19 on Wednesday, hitting $3.62. 292,990 shares of the company’s stock were exchanged, compared to its average volume of 524,230. Exagen Inc. has a 1 year low of $2.77 and a 1 year high of $12.23. The company has a 50-day simple moving average of $4.52 and a 200-day simple moving average of $7.76. The company has a debt-to-equity ratio of 1.35, a quick ratio of 4.08 and a current ratio of 4.08. The stock has a market capitalization of $82.03 million, a PE ratio of -3.93 and a beta of 1.88.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Bridgeway Capital Management LLC boosted its stake in Exagen by 10.3% during the second quarter. Bridgeway Capital Management LLC now owns 27,800 shares of the company’s stock valued at $194,000 after buying an additional 2,600 shares during the last quarter. Calamos Advisors LLC boosted its position in shares of Exagen by 3.5% during the 3rd quarter. Calamos Advisors LLC now owns 78,090 shares of the company’s stock valued at $858,000 after acquiring an additional 2,677 shares during the last quarter. Truvestments Capital LLC grew its holdings in shares of Exagen by 109.5% in the fourth quarter. Truvestments Capital LLC now owns 6,169 shares of the company’s stock valued at $38,000 after purchasing an additional 3,225 shares in the last quarter. State Street Corp increased its position in Exagen by 6.9% in the fourth quarter. State Street Corp now owns 71,256 shares of the company’s stock worth $433,000 after purchasing an additional 4,600 shares during the last quarter. Finally, Huntleigh Advisors Inc. raised its stake in Exagen by 6.3% during the third quarter. Huntleigh Advisors Inc. now owns 93,353 shares of the company’s stock valued at $1,026,000 after purchasing an additional 5,492 shares in the last quarter. Hedge funds and other institutional investors own 75.25% of the company’s stock.

Analysts Set New Price Targets

XGN has been the topic of a number of recent analyst reports. BTIG Research decreased their target price on shares of Exagen from $15.00 to $10.00 and set a “buy” rating on the stock in a research note on Tuesday, February 17th. TD Cowen decreased their price objective on shares of Exagen from $13.00 to $10.00 and set a “buy” rating on the stock in a research report on Tuesday, February 24th. B. Riley Financial reaffirmed a “buy” rating and issued a $8.00 target price (down from $18.00) on shares of Exagen in a report on Friday, January 30th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Exagen in a report on Wednesday, January 21st. Nine investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $11.43.

About Exagen

Exagen Inc is a molecular diagnostics company focused on improving the detection and management of autoimmune diseases. Headquartered in the United States, the company develops, manufactures and markets laboratory tests designed to help clinicians address diagnostic challenges associated with complex connective tissue disorders.

The company’s flagship product portfolio, marketed under the Avise® brand, includes multi-analyte assays such as the Avise® Connective Tissue Disease (CTD) panel, Avise® Lupus panel and Avise® Sjögren’s panel.